Section snippets

Abbreviations

Metabolic dysfunction-associated steatotic liver disease (MASLD), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH)”Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a very common liver disease in the general population with an especially high

Uncited reference

2.; 3.; 4.; 15..

Funding

No funding was received for this work.

Declaration of Competing Interest

ZMY has received research funding and/or serve as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madridgal, Merck and Abbott

中文翻译：

---

回复： “”Fatty“ or ”steatotic“： Chinese Speaking Community 从语言学角度看的立场陈述”

 部分片段

 缩写

代谢功能障碍相关脂肪性肝病 （MASLD）、非酒精性脂肪性肝病 （NAFLD）、2 型糖尿病 （T2D）、代谢功能障碍相关脂肪肝病 （MAFLD）、非酒精性脂肪性肝炎 （NASH）、代谢功能障碍相关脂肪性肝炎 （MASH）“代谢功能障碍相关脂肪性肝病 （MASLD），以前称为非酒精性脂肪性肝病 （NAFLD），是普通人群中非常常见的肝病，其

 未引用的参考文献

2.; 3.; 4.; 15..

 资金

这项工作没有收到任何资金。

利益争夺声明

ZMY 已获得研究资助和/或担任 Intercept、CymaBay、勃林格殷格翰、百时美施贵宝、葛兰素史克、诺和诺德、益普生、阿斯利康、西门子、马德里、默克和雅培的顾问